Allison Dorval, Chief Financial Officer at Verve Therapeutics, Inc. (VERV), sold 555 shares at $5.64 ($3K) on 2024-12-02, disclosed to the SEC on 2024-12-03.
Open-market sale of $3k VERV by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| VERV | SELL | 2025-04-03 | $14K | — | Filing → |
| PBYI | SELL | 2024-06-17 | $37K | — | Filing → |
| VERV | SELL | 2023-12-01 | $6K | — | Filing → |